問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Thoracic Medicine

Division of Hematology & Oncology

Division of General Internal Medicine

更新時間：2023-09-19

涂智彥Tu, Chih-Yen
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

  • D7855@mail.cmuh.org.tw

Recruiting Trial

75Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

涂智彥

List

168Cases

2013-03-01 - 2014-12-31

Phase III

A 26-week multi-center randomized double-blind study to compare efficacy and safety of NVA237 versus placebo as an add-on to maintenance therapy with fixed-dose combination salmeterol/ fluticasone propionate in COPD patients with moderate to severe airflow limitation.

  • Condition/Disease

    COPD

  • Test Drug

    NVA237

Participate Sites
9Sites

Terminated9Sites

2018-08-01 - 2020-04-07

Phase III

A 2-treatment period, randomized, placebo-controlled, multicenter parallelgroup study to assess the safety of QAW039 when added to existing asthma therapy in GINA steps 3, 4 and 5 patients with uncontrolled asthma.

  • Condition/Disease

    asthma

  • Test Drug

    QAW039

Participate Sites
2Sites

Terminated1Sites

Study ended1Sites

2022-09-01 - 2024-07-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting2Sites

Terminated4Sites

2017-02-10 - 2025-12-31

Phase III

A Global, Randomized, Phase 3, Open-Label Study of REGN2810 (Anti PD 1 Antibody) versus Platinum Based Chemotherapy in First Line Treatment of Patients with Advanced or Metastatic PD L1 + Non-Small Cell Lung Cancer

  • Condition/Disease

    NSCLC

  • Test Drug

    REGN2810

Participate Sites
17Sites

Recruiting13Sites

Terminated2Sites

夏德椿
China Medical University Hospital-Taipei

未分科

張家崙
Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Hematology & Oncology

2023-06-01 - 2030-05-31

Phase II/III

A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression Levels

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    Fianlimab (REGN3767)Cemiplimab (REGN2810)

Participate Sites
9Sites

Recruiting9Sites

2020-09-01 - 2023-09-20

Phase I

A Phase 1b Study of ASP1951, a GITR Agonistic Antibody, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    ASP1951

Participate Sites
3Sites

Recruiting3Sites

邱昌芳
China Medical University Hospital

Division of Hematology & Oncology

2022-11-30 - 2027-10-31

Phase III

A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)

  • Condition/Disease

    Metastatic Non Small Cell Lung Cancer

  • Test Drug

    Datopotamab deruxtecan (Dato-DXd；DS-1062a)

Participate Sites
9Sites

Recruiting9Sites

2020-09-20 - 2024-02-22

Phase I

A Phase I, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of OBI-866/OBI-821, a Novel Anti-Stage-Specific Embryonic Antigen-4 (SSEA-4) Active Immunotherapy, in Patients with Advanced/Metastatic Cancers of the Ovary, Kidney, Brain, Pancreas, Breast or Lung

  • Condition/Disease

    Cancers of the Ovary, Kidney, Brain, Pancreas, Breast or Lung

  • Test Drug

    OBI-866 (SSEA-4) / OBI-821 (adjuvant)

Participate Sites
2Sites

Recruiting2Sites

白禮源
China Medical University Hospital

Division of Hematology & Oncology

2009-06-01 - 2011-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2011-03-01 - 2015-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

1 13 14 15 16 17
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB